Current Targets for Primary Sclerosing Cholangitis

Author(s): Irene Pierantonelli*, Antonio Benedetti, Marco Marzioni.

Journal Name: Current Drug Targets

Volume 18 , Issue 8 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Primary sclerosing cholangitis (PSC) is a biliary disease characterized by liver inflammation and death of cholangiocytes which, in turn, drive to fibrosis, cirrhosis and functional alterations of the liver. PSC is also associated with an increased risk of developing cholangiocarcinoma. To date, the etiopathogenesis of PSC is still not completely understood, although a genetic predisposition in association to environmental factors contribute to immune-mediated liver damage. The lack of such knowledge is responsible for the failure of most available therapies. At this time, many studies are evaluating potential approaches that could have a positive impact on the progression of the disease. This review aims to provide a summary of present and past therapeutic approaches for PSC.

Keywords: Primary sclerosing cholangitis, cholestasis, pathogenesis, inflammatory bowel disease, diagnosis, treatment.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [901 - 907]
Pages: 7
DOI: 10.2174/1389450117666160112114152
Price: $65

Article Metrics

PDF: 34
PRC: 1